Actavis, the former Watson Pharmaceuticals, said its fourth-quarter earnings paled by comparison to a year ago when it first released an official generic of Lipitor.
India's Ranbaxy Laboratories' manufacturing problems have devastated its share of the U.S. generic Lipitor market. On top of that, an expanded lawsuit in New Jersey seeks to have the drugmaker recall all of the drug that it has in the U.S.
Pfizer ($PFE) racked up a 46% increase in full-year profits. But its sales fell 10%. How so? Pfizer's sale of the nutrition business, which went to Nestle for $11.85 billion, helped boost reported net income to $14.57 billion.
While FiercePharma 's newsletter went on hiatus over the winter holidays--and industry news slowed to a pace suitable to hibernation-friendly weather--we didn't spend all our time skiing and drinking cocoa. Some certifiably big news broke last week. Here are several holiday highlights.
It is another swing and a miss for Mylan. Twice now it has struck out in efforts to snatch away from Ranbaxy Laboratories the Indian drugmaker's 180-day exclusivity on a drug.
It's the end of the year, and the end of the road for hundreds of Pfizer drug reps. The company is slashing its primary-care sales force by almost 20%, Bloomberg reports, taking its 3,000-strong army of reps down to around 2,400.
By the time the ball drops in Times Square this year, branded drug sales will have dropped 3.5%. So says a new report on U.S. spending, which pegs this year's decline at that rate--and forecasts an annual decline of 2.6%, on average, over the next several years.
Pfizer's animal health unit may be worth $20 billion, and that is the conundrum.
Generic drugmaker Mylan ($MYL), impatient that money is sitting on the table, has sued the FDA to try to snatch the rights to produce a generic of Novartis' ($NVS) blockbuster blood pressure med, Diovan.
Ranbaxy Laboratories is investigating whether splintered glass from the lining of a reactor at a plant in India is the source of particles found in the raw ingredients for generic Lipitor that were delivered to a Ranbaxy plant in the U.S. where the pills are finished.